Gastroesophageal Reflux
Conditions
Keywords
Safety
Brief summary
The purpose of this study is to provide additional information on safety and tolerability after multiple does of pantoprazole. Only patients who successfully completed the 3001B3-331 study (NCT00362609) or 3001B3-333 study (NCT00259012) are eligible to participate in this study.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* Successful completion of the 3001B3-331 study (NCT00362609) or 3001B3-333 study (NCT00259012) Study.
Exclusion criteria
* Patients requiring chronic use of warfarin, carbamepazine, or phenytoin.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | 6 weeks | Pre-defined criteria were established for each laboratory test to define the values that would be identified as of potential clinical importance. Criteria are as follows: Potassium ≤ 3.0 mEq/L or ≥ 6.2 mEq/L; Carbon dioxide \< 12 mEq/L or \> 35 mEq/L; Total bilirubin \> 1.5xULN; CPK \> 3xULN; Gastrin ≥ 600 pg/mL; Neutrophils \< 10% or \> 80%; Platelet count \< 100 x10 to the third power/ul or \> 600 x10 to the third power/ul; Urine protein albumin \> 2+ (dipstick) 100mg/dL or positive; Urine leukocyte esterase \> 2+ (dipstick) moderate or positive. |
| Growth Parameters Z-scores | 6 weeks | Z-Score is a statistical measure to evaluate how a single data point compares to a standard. A Z-Score describes whether a mean is above or below the standard and how unusual the measurement is. Z-scores primarily range from -3 to +3. A Z-score of 0 indicates the same mean, \>0 a greater mean, and \<0 a lesser mean than the standard. In this study, infant growth parameters were compared to a standard defined by Centers for Disease Control's growth charts. |
Countries
Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, South Africa, Switzerland, United States
Participant flow
Recruitment details
Patients were recruited worldwide March 2006 to February 2008.
Pre-assignment details
Patients were eligible for enrollment into the study after completion of either study 3001B3-331 (NCT00362609) or study 3001B3-333 (NCT00259012).
Participants by arm
| Arm | Count |
|---|---|
| Low Dose Pantoprazole Patients who participated previously in study 3001B3-333 (NCT00259012) (infants) and weighed 2.5 to \<7 kg generally received pantoprazole sodium enteric-coated spheroid suspension daily 2.5 mg; those weighing ≥ 7 kg to ≤ 15 kg generally received pantoprazole sodium enteric-coated spheroid suspension daily 5 mg. (A patient's dose may have been increased from the dose used in the previous study at the start of this open label extension study to manage clinical symptoms) No patients who participated previously in study 3001B3-331 (NCT00362609) (pre-term/neonates) were included in the low dose group. | 12 |
| High Dose Pantoprazole Patients who participated previously in study 3001B3-333 (NCT00259012) (infants) and weighed 2.5 to \<7kg generally received pantoprazole sodium enteric-coated spheroid suspension daily 5 mg; those weighing ≥ 7 kg to ≤ 15 kg generally received pantoprazole sodium enteric-coated spheroid suspension daily 10 mg. (A patient's dose may have been increased from the dose used in the previous study at the start of this open label extension study to manage clinical symptoms.) All patients who participated previously in study 3001B3-331 (NCT00362609) (pre-term/neonates) received 2.5 mg (or higher, if the dose was increased at the start of this open label extension study to manage clinical symptoms) and were classified as part of the high dose group for analysis purposes. | 46 |
| Total | 58 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 0 | 2 |
| Overall Study | Withdrawal by Subject | 0 | 1 |
Baseline characteristics
| Characteristic | Low Dose Pantoprazole | High Dose Pantoprazole | Total |
|---|---|---|---|
| Age Continuous | 7.34 months STANDARD_DEVIATION 3.06 | 5.55 months STANDARD_DEVIATION 3.44 | 5.92 months STANDARD_DEVIATION 3.42 |
| Sex: Female, Male Female | 5 Participants | 21 Participants | 26 Participants |
| Sex: Female, Male Male | 7 Participants | 25 Participants | 32 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 8 / — | 30 / — |
| serious Total, serious adverse events | 1 / — | 2 / — |
Outcome results
Growth Parameters Z-scores
Z-Score is a statistical measure to evaluate how a single data point compares to a standard. A Z-Score describes whether a mean is above or below the standard and how unusual the measurement is. Z-scores primarily range from -3 to +3. A Z-score of 0 indicates the same mean, \>0 a greater mean, and \<0 a lesser mean than the standard. In this study, infant growth parameters were compared to a standard defined by Centers for Disease Control's growth charts.
Time frame: 6 weeks
Population: Safety population (all patients with ≥1 dose of study drug) who also had baseline and end of study evaluations. Data point pairs were analyzed. All patients in study 3001B3-335 originated from study 3001B3-331 or -333 and baselines from the original study they were in were used.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Low Dose Pantoprazole | Growth Parameters Z-scores | Length - Baseline (n=12, 45) | 0.33 units on scale | Standard Deviation 1.11 |
| Low Dose Pantoprazole | Growth Parameters Z-scores | Length - Final evaluation (n=12, 45) | 0.45 units on scale | Standard Deviation 1.29 |
| Low Dose Pantoprazole | Growth Parameters Z-scores | Weight - Baseline (n=12, 46) | -0.16 units on scale | Standard Deviation 1.15 |
| Low Dose Pantoprazole | Growth Parameters Z-scores | Weight - Final evaluation (n=12, 46) | -0.05 units on scale | Standard Deviation 1.33 |
| Low Dose Pantoprazole | Growth Parameters Z-scores | Head circumference - Baseline (n=11, 45) | 0.31 units on scale | Standard Deviation 1.17 |
| Low Dose Pantoprazole | Growth Parameters Z-scores | Head circumference - Final evaluation (n=11, 45) | 0.25 units on scale | Standard Deviation 1.21 |
| High Dose Pantoprazole | Growth Parameters Z-scores | Head circumference - Baseline (n=11, 45) | -1.06 units on scale | Standard Deviation 2.1 |
| High Dose Pantoprazole | Growth Parameters Z-scores | Length - Baseline (n=12, 45) | -1.63 units on scale | Standard Deviation 2.99 |
| High Dose Pantoprazole | Growth Parameters Z-scores | Weight - Final evaluation (n=12, 46) | -1.00 units on scale | Standard Deviation 1.73 |
| High Dose Pantoprazole | Growth Parameters Z-scores | Length - Final evaluation (n=12, 45) | -1.04 units on scale | Standard Deviation 2.52 |
| High Dose Pantoprazole | Growth Parameters Z-scores | Head circumference - Final evaluation (n=11, 45) | -0.62 units on scale | Standard Deviation 1.71 |
| High Dose Pantoprazole | Growth Parameters Z-scores | Weight - Baseline (n=12, 46) | -1.26 units on scale | Standard Deviation 1.9 |
Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period
Pre-defined criteria were established for each laboratory test to define the values that would be identified as of potential clinical importance. Criteria are as follows: Potassium ≤ 3.0 mEq/L or ≥ 6.2 mEq/L; Carbon dioxide \< 12 mEq/L or \> 35 mEq/L; Total bilirubin \> 1.5xULN; CPK \> 3xULN; Gastrin ≥ 600 pg/mL; Neutrophils \< 10% or \> 80%; Platelet count \< 100 x10 to the third power/ul or \> 600 x10 to the third power/ul; Urine protein albumin \> 2+ (dipstick) 100mg/dL or positive; Urine leukocyte esterase \> 2+ (dipstick) moderate or positive.
Time frame: 6 weeks
Population: Patients who received ≥1 dose of pantoprazole and had laboratory test results. The number of patients (n) tested varied by test, variations shown (low dose, high dose): Carbon dioxide (n=7,26), CPK (n=12,42), Gastrin (n=9,25), Neutrophils (n=12,44), Platelet count (n=12,41), Urine protein albumin (n=10,38), Urine leukocyte esterase (n=10,38).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Low Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | Carbon dioxide (mmol/L) | 0 patients |
| Low Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | Neutrophils (1,000,000,000/L) | 1 patients |
| Low Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | CPK (mU/mL) | 0 patients |
| Low Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | Platelet count (1,000,000,000/L) | 0 patients |
| Low Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | Total bilirubin (µmol/L) | 0 patients |
| Low Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | Urine protein albumin | 0 patients |
| Low Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | Gastrin (pg/mL) | 0 patients |
| Low Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | Urine leukocyte esterase | 1 patients |
| Low Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | Potassium (mmol/L) | 0 patients |
| High Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | Urine leukocyte esterase | 3 patients |
| High Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | Potassium (mmol/L) | 3 patients |
| High Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | Carbon dioxide (mmol/L) | 1 patients |
| High Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | Total bilirubin (µmol/L) | 1 patients |
| High Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | CPK (mU/mL) | 2 patients |
| High Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | Gastrin (pg/mL) | 1 patients |
| High Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | Neutrophils (1,000,000,000/L) | 0 patients |
| High Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | Platelet count (1,000,000,000/L) | 2 patients |
| High Dose Pantoprazole | Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period | Urine protein albumin | 1 patients |